Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum
March 16, 2022 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022
March 01, 2022 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility
January 10, 2022 08:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments
December 07, 2021 16:05 ET | Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $26.1 Million -- -- Initiated Strategic Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy -- -- Signed $36 Million in...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer
October 07, 2021 08:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments
September 08, 2021 16:05 ET | Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $30.8 Million -- -- Achieved Fifth Consecutive Quarter of Operational Profitability -- --  Signed $23 Million in New Business Orders and Ended the Quarter...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Participate at Upcoming Investor Conferences
September 02, 2021 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors
July 01, 2021 08:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments
June 29, 2021 16:05 ET | Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 -- -- Signed...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
May 25, 2021 08:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...